CDH17 and cancer: Loss of heterozygosity and inactivating gene mutations, epigenetic silencing at the cancer site, transcriptional repression, cadherin replacement, endocytosis, and proteolytic processing are some of the mechanisms correlated with E-cad inhibition [52].